<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055183</url>
  </required_header>
  <id_info>
    <org_study_id>BT-010</org_study_id>
    <nct_id>NCT02055183</nct_id>
  </id_info>
  <brief_title>BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin</brief_title>
  <official_title>Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Registry was to evaluate patient safety following Botulism Antitoxin&#xD;
      Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) administration in adult and pediatric&#xD;
      patients with a confirmed or suspected exposure to botulinum toxin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A full description of the patient registry can be found in the paper titled: Safety and&#xD;
      Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for&#xD;
      Confirmed or Suspected Botulism in the United States. Richardson JS, Parrera GS, Astacio H,&#xD;
      Sahota H, Anderson DM, Hall C, Babinchak T. Clin Infect Dis. 2019 Apr 15;70(9):1950-1957.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Number of participants with serious and non-serious adverse events</measure>
    <time_frame>From BAT® administration up to discharge from hospital (200 days)</time_frame>
    <description>The data obtained will more clearly define the absolute risk (incidence rates) of hypersensitivity/allergic reactions, including serum sickness, febrile reactions, hemodynamic instability, bradycardia, and other serious adverse events in pediatric and adult patients that are treated with BAT® due to a confirmed or suspected case of botulism.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of participants developing acute hypersensitivity</measure>
    <time_frame>24 hours</time_frame>
    <description>Reactions that may occur shortly after exposure to BAT® and can include, but are not limited to, urticaria, pruritus, erythema, angioedema, bronchospasm with wheezing or cough, stridor, laryngeal edema, hypotension, or tachycardia.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing anaphylaxis /anaphylactoid reactions</measure>
    <time_frame>24 hours</time_frame>
    <description>Severe form of acute, severe hypersensitivity reaction with multiorgan system involvement that occurs with sudden onset after exposure to an allergen. Case definition of anaphylaxis requires a sudden onset and rapid progression of signs and symptoms and involvement of multiple (≥ 2) organ systems (cardiovascular, dermatological or respiratory).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing delayed allergic reaction or serum sickness</measure>
    <time_frame>10-21 days</time_frame>
    <description>This includes symptoms such as, but not limited to, fever, urticarial or maculopapular rash, myalgia, arthralgia, and lymphadenopathy occurring 10-21 days after BAT® infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing infusion reactions</measure>
    <time_frame>24 hours</time_frame>
    <description>Infusion reactions are unexpected reactions that cannot be explained by the known toxicity profile of the drug. Infusion reactions are the result of the infusion process (rate, volume, etc.) and are often referred to as &quot;hypersensitivity reactions&quot; as well. In the absence of an allergic component, the term &quot;infusion reaction&quot; is preferred. Infusion reactions may affect any organ system in the body. Most are mild in severity, although severe and fatal reactions may occur. The most common signs and symptoms may include, but are not limited to flushing, itching, alterations in heart rate and blood pressure, dyspnea or chest discomfort, back or abdominal pain, fever and/or shaking chills (rigors), nausea, vomiting, and/or diarrhea, skin rashes, throat tightening, hypoxia, seizures, dizziness and/or syncope.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing febrile reactions</measure>
    <time_frame>1 hour</time_frame>
    <description>Febrile reaction is an absolute temperature &gt; 38.1°C or an increase in temperature &gt;1°C above baseline temperature that occurs during or within 1 hour of BAT® infusion and is unrelated to the underlying illness.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing hemodynamic instability</measure>
    <time_frame>24 hours</time_frame>
    <description>A state requiring pharmacologic or mechanical support to maintain a normal blood pressure or adequate cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants developing bradycardia</measure>
    <time_frame>24 hours</time_frame>
    <description>Bradycardia is defined as an abnormally slow heart rate; usually &lt;60 beats per minute in adults.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">162</enrollment>
  <condition>Botulism</condition>
  <arm_group>
    <arm_group_label>Participants treated with BAT®</arm_group_label>
    <description>Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT</intervention_name>
    <description>Noninterventional, retrospective, observational phase 4 patient Registry</description>
    <arm_group_label>Participants treated with BAT®</arm_group_label>
    <other_name>Botulism Antitoxin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient of any age [age category: pediatric-newborn infants (0 to 27 days), infants and&#xD;
        toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to&#xD;
        &lt;17-years); adult (17-64-years); and geriatric (≥65-years)] with a confirmed or suspected&#xD;
        exposure to botulinum toxin who were treated with BAT® provided by the CDC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient of any age [age category: pediatric-newborn infants (0 to 27 days),&#xD;
             infants and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents&#xD;
             (12 to &lt;17-years); adult (17-64-years); and geriatric (≥65-years)] with a confirmed or&#xD;
             suspected exposure to botulinum toxin who were treated with BAT® provided by the CDC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason S Richardson, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <link>
    <url>http://www.cdc.gov/mmwr/pdf/wk/mm5910.pdf</url>
    <description>Morbidity and Mortality Weekly Report Center for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT™) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM345147.pdf</url>
    <description>Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT™) United States Prescribing Information, 03/2013.</description>
  </link>
  <reference>
    <citation>Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001 Feb 28;285(8):1059-70. Review. Erratum in: JAMA 2001 Apr 25;285(16):2081.</citation>
    <PMID>11209178</PMID>
  </reference>
  <reference>
    <citation>Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980 Oct;69(4):567-70.</citation>
    <PMID>7191633</PMID>
  </reference>
  <reference>
    <citation>Gangarosa EJ, Donadio JA, Armstrong RW, Meyer KF, Brachman PS, Dowell VR. Botulism in the United States, 1899-1969. Am J Epidemiol. 1971 Feb;93(2):93-101.</citation>
    <PMID>4925448</PMID>
  </reference>
  <reference>
    <citation>Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth. 1997 May;78(5):601-5. Erratum in: Br J Anaesth 1997 Aug;79(2):268.</citation>
    <PMID>9175982</PMID>
  </reference>
  <reference>
    <citation>Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, Bernstein JA, Burks AW, Feldweg AM, Fink JN, Greenberger PA, Golden DB, James JM, Kemp SF, Ledford DK, Lieberman P, Sheffer AL, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang D, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010 Sep;126(3):477-80.e1-42. doi: 10.1016/j.jaci.2010.06.022. Epub 2010 Aug 7. Erratum in: J Allergy Clin Immunol. 2010 Dec;126(6):1104.</citation>
    <PMID>20692689</PMID>
  </reference>
  <reference>
    <citation>Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 1;25(31):5675-84. Epub 2007 Mar 12.</citation>
    <PMID>17448577</PMID>
  </reference>
  <reference>
    <citation>Schleis TG. Interference of maltose, icodextrin, galactose, or xylose with some blood glucose monitoring systems. Pharmacotherapy. 2007 Sep;27(9):1313-21.</citation>
    <PMID>17723085</PMID>
  </reference>
  <reference>
    <citation>Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998 Aug 1;129(3):221-8. Review.</citation>
    <PMID>9696731</PMID>
  </reference>
  <reference>
    <citation>Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984 May;76(5):794-8.</citation>
    <PMID>6720725</PMID>
  </reference>
  <results_reference>
    <citation>Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T. Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States. Clin Infect Dis. 2020 Apr 15;70(9):1950-1957. doi: 10.1093/cid/ciz515.</citation>
    <PMID>31209461</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Registry</keyword>
  <keyword>Botulinum antitoxin</keyword>
  <keyword>Botulism Antitoxin Heptavalent- (Equine)</keyword>
  <keyword>BAT®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antitoxins</mesh_term>
    <mesh_term>Botulinum Antitoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

